ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2547

Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action.
Abstract Number: 2271

Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Abstract Number: 1059

Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children
Abstract Number: 1895

Assessing the Validity of Self-Reported Medication Data Through Metabolite Analysis: Data from the Osteoarthritis Initiative
Abstract Number: 0363

Assessing Whole Health Needs in Systemic Lupus Erythematosus
Abstract Number: 1391

Assessment of Anti-SSA/Ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Abstract Number: 0279

Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Abstract Number: 1154

Assessment Of Damage Using The IgG4-Related Disease Damage Index.
Abstract Number: 1422

Assessment of difficulties, modifications and use of work adaptations in patients with axial spondyloarthritis: validation of the DificuLtAx and ModAL questionnaires
Abstract Number: 1333

Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
Abstract Number: 0455

Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
Abstract Number: 2262

Assessment of small airway disease in rheumatoid arthritis
Abstract Number: 0604

Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
Abstract Number: 1041

Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
Abstract Number: 0516

Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].